A breakthrough medication for endometriosis has been approved for use, bringing hope to those suffering from the debilitating condition. The new combination drug, relugolix–estradiol–norethisterone, also known as relugolix combination therapy or Ryeqo, is the first daily pill licensed for long-term treatment of endometriosis.
This approval represents a significant advancement over current treatment options, offering a more convenient and potentially less strenuous experience for patients. The medication is expected to benefit approximately 1,000 individuals each year by providing an alternative to existing injectable treatments.
The pill works by blocking specific hormones that contribute to endometriosis while simultaneously supplying necessary hormone replacement. This dual-action approach targets the root cause of the condition while helping to reduce potential side effects. Unlike injectable treatments, which can initially worsen symptoms, this pill can be taken at home and provides faster relief. By combining multiple hormones in a single pill, it eliminates the need for frequent clinical visits.
Endometriosis is a chronic condition where tissue similar to the lining of the womb grows in other parts of the body, often affecting the pelvis, bladder, and bowel. It can cause severe pain, heavy periods, fatigue, and fertility issues, significantly impacting the personal and professional lives of those affected.
Approximately 1.5 million people in the UK are believed to suffer from endometriosis. However, diagnosis often takes an average of nine years from the onset of symptoms due to similarities with other conditions such as fibroids, pelvic inflammatory disease, and irritable bowel syndrome.
Initially, health authorities declined approval for the drug due to concerns about effectiveness and cost. However, further evidence provided by the manufacturer helped address these concerns, leading to its eventual approval.
The medication will be available only to those for whom other medical or surgical treatments have failed. It offers greater flexibility compared to existing options, as it can be stopped and restarted more easily. This feature is particularly beneficial for those planning to conceive or managing side effects.
Health experts have emphasized that this new treatment marks a significant change in the management of endometriosis. By reducing the need for frequent medical visits, it not only empowers patients to take control of their condition but also helps alleviate pressure on healthcare services.
The cost of the treatment has been set at £72 for a 28-day supply, excluding VAT. While not a universal solution for all endometriosis sufferers, this new pill provides a much-needed alternative for those struggling with the limitations of existing treatments.
